MONTREAL, CANADA -- (MARKET WIRE) -- December 04, 2006 -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced today that its UK subsidiary ProMetic Biosciences Ltd ("PBL") has entered into an agreement with Novartis Vaccines and Diagnostics GmbH & Co.K.G (NYSE: NVS) ("Novartis"), to develop a synthetic-ligand affinity adsorbent for the purification of a recombinant protein vaccine. Under the terms of the agreement PBL will receive funding from Novartis to screen its Chemical Combinatorial Libraries® for ligands suitable for the processscale purification of a new vaccine product developed by Novartis and currently undergoing clinical trials. The work is to be conducted at PBL's research laboratories located at the Cambridge Science Park, UK.
